Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis

References

1. Aisen P. 1980; The transferrins. In Iron in Biochemistry and Medicine pp 87–123 Edited by Jacobs A., Worwood M. London, UK: Academic Press;
   [Google Scholar]
2. Canetti G. 1955 The Tubercle Bacillus in the Pulmonary Lesion of Man New York: Springer;
   [Google Scholar]
3. Cole S. T., Brosch R., Parkhill J. & 39 other authors; 1998; Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537–544 [CrossRef]
   [Google Scholar]
4. Heifets L., Lindholm-Levy P. 1992; Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 145:1223–1225 [CrossRef]
   [Google Scholar]
5. McDermott W., Tompsett R. 1954; Activation of pyrazinamide and nicotinamide in acidic environments in vitro . Am Rev Tuberc 70:748–754
   [Google Scholar]
6. Mitchison D. 1985; The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66:219–225 [CrossRef]
   [Google Scholar]
7. Somoskovi A., Wade M. M., Sun Z., Zhang Y. 2004; Iron enhances the antituberculous activity of pyrazinamide. J Antimicrob Chemother 53:192–196 [CrossRef]
   [Google Scholar]
8. Tarshis M. S., Weed W. A. Jr 1953; Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. Am Rev Tuberc 67:391–395
   [Google Scholar]
9. Wayne L. G., Hayes L. G. 1996; An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64:2062–2069
   [Google Scholar]
10. Zhang Y., Telenti A. 2000; Genetics of drug resistance in Mycobacterium tuberculosis . In Molecular Genetics of Mycobacteria pp 235–254 Edited by Hatfull G., Jacobs W. R. Jr Washington, DC: ASM Press;
    [Google Scholar]
11. Zhang Y., Mitchison D. A. 2003; The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7:6–21
    [Google Scholar]
12. Zhang Y., Scorpio A., Nikaido H., Sun Z. H. 1999; Role of acid pH and deficient efflux of pyrazinoic acid in the unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 181:2044–2049
    [Google Scholar]
13. Zhang Y., Permar S., Sun Z. 2002; Conditions that may affect the results of Mycobacterium tuberculosis susceptibility testing to pyrazinamide. J Med Microbiol 51:42–49
    [Google Scholar]
14. Zhang Y., Wade M. M., Scorpio A., Zhang H., Sun Z. 2003; Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 52:790–795 [CrossRef]
    [Google Scholar]